Superior Patency and Reduced Interventions Versus Balloon Angioplasty Alone for Challenging AV Access Cases with VIAHBAN from GORE

Today GORE announced the study results from the Gore REVISE Clinical Study* in the Journal of Vascular Surgery detailing the success of the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface (GORE VIABAHN Endoprosthesis) in AV access graft outflow interventions. Overall, the device performed significantly better compared to percutaneous transluminal angioplasty (PTA) alone for treatment of challenging AV access cases in a real-world patient population, both in terms of primary patency and in number of interventions over the study period. Notably, the Gore REVISE Clinical Study is the first AV access stent-graft study to include patients with thrombosed grafts and placement of the device across the elbow joint, further demonstrating the utility of the VIABAHN Endoprosthesis in this demanding clinical application.

Interventionalists treating patients suffering from Peripheral Vascular Disease (PVD) in the Superficial Femoral Artery (SFA) require a flexible stent-graft capable of re-lining tortuous arteries.
The GORE® VIABAHN® Endoprosthesis is constructed with a durable, reinforced, biocompatible, expanded polytetrafluoroethylene (ePTFE) liner attached to an external nitinol stent structure. The flexibility of the GORE® VIABAHN® Endoprosthesis enables it to traverse tortuous areas of the SFA and conform closely to the complex anatomy of the artery. The GORE® VIABAHN® Endoprosthesis is also available with CBAS Heparin Surface.
The GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface is the only device of its kind approved for both the SFA and iliac artery. The stent-graft features the addition of proprietary heparin-bonded technology to the proven combination of ePTFE and nitinol. End-point covalent bonding keeps heparin anchored to the endoprosthesis surface while the bioactive site remains free to interact with the blood.
With a lower profile, the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface offers more options for endoluminal bypass. This next generation device enables a reduction in delivery profile to 6 Fr for 5 and 6 mm devices and 7 Fr for 7 and 8 mm devices and is delivered over a 0.018″ or 0.014″ guidewire.

Source BWire and GORE